

Breast cancer accounts for **11.7% (2.261 million new cases)** of the global cancer incidence and **6.9% (684 996 deaths)** of the global cancer mortality (Source: GLOBOCAN 2020).

This fact sheet presents the screening protocol, number of women screened and performance indicators according to the most up-to-date information received from **75 countries**.

The year of data collection may differ across the countries.

Reporting year	Screening test	Screening interval (years)	Age group	Number screened	Examination coverage (%)	Proportion advised further assessment (%)	Further assessment participation rate (%)	Detection rate of CIS (/1,000)	Detection rate of invasive cancer (/1,000)	PPV to detect CIS invasive cancer (%)
AFRICA										
Botswana	2021	No programme (demonstration project on-going)								
Cabo Verde	2021	No programme								
Cameroon	2022	No programme								
Côte d'Ivoire	2020	No programme								
Ethiopia	2021	No programme								
Kenya	2020	CBE	2	25+	—	—	—	—	—	—
	2020	Mx	1/2	40+	—	—	—	—	—	—
Libya	2021	No programme								
Malawi	2022	No programme								
Morocco	2019	CBE	2	40-69	1,515,586	56.2	2.4	39.7	—	0.9
Mozambique	2020	CBE	1	25-45	2,453,675	54.9	1.0	—	—	—
Namibia	2021	No programme								
Rwanda	2020	No programme								
South Africa	2020	CBE	1	30-50	—	—	—	—	—	—
Uganda	2021	No programme								
United Republic of Tanzania	2021	No programme								
Zimbabwe	2021	No programme								
AMERICAS										
Antigua and Barbuda	2021	No programme								
Bahamas	2022	No programme								
Brazil	2020	Mx	2	50-69	—	—	—	—	—	—
Canada, Manitoba	2020	Mx	2	50-74	—	—	—	—	—	—
Colombia	2020	Mx	2	50-69	—	—	—	—	—	—
Colombia	2020	CBE	1	40-69	—	—	—	—	—	—
Chile	2020	Mx/CBE	3	50-69	—	—	—	—	—	—
Cuba	2021	CBE	1	30-99	—	—	—	—	—	—
Dominica	2021	No programme								
Ecuador	2019	No programme (pilot project on-going)								
El Salvador	2020	Mx	1	40-69	—	—	—	—	—	—
Grenada	2021	No programme								
Guyana	2021	No programme								
Guatemala	2021	No programme								
Honduras	2021	No programme								
Jamaica	2021	Mx	1	40-69	—	—	—	—	—	—
	2020	CBE	2	25-39	—	—	—	—	—	—
Mexico [^]	2020	Mx	2	40-69	1,125,869	14.9	0.9	76.2	0.4	5.0
Nicaragua	2019	Mx	1/2	40+	24,218	3.5	2.9	—	—	—
Panama	2020	Mx/CBE	2	40-74	—	—	—	—	—	—
Paraguay	2020	Mx	1	40-65	—	—	—	—	—	—
Saint Kitts and Nevis	2021	No programme								
Saint Lucia	2021	No programme								
Suriname	2021	Mx	2	50-75	—	—	—	—	—	—
Uruguay	2019	Mx	2	50-69	81,497	52.9	1.6	—	—	—
ASIA										
Bangladesh	2019	CBE	1	30+	384,267	1.7	2.8	—	—	—
China, Henan	2021	CBE/US	5	30-64	—	—	—	—	—	—
China, Tianjin	2021	US	1	40-74	—	—	—	—	—	—
India, Assam	2020	CBE	5	30-69	—	—	—	—	—	—
Japan	2017	Mx	2	40+	3,087,781	15.1	6.0	92.9*	0.4	2.8
Republic of Korea	2016	Mx	2	40+	3,712,924	56.7	14.4	—	0.4	2.0
Thailand	2019	CBE	1	40-79	—	—	—	—	—	—
Turkey	2019	Mx	2	40-69	—	—	—	—	—	—
	2019	CBE	1	40-69	—	—	—	—	—	—

Legend:

CBE: clinical breast examination; CIS: carcinoma in situ of breast; Mx: mammography; US: Ultrasound
only for invasive cancer

* including women with negative screening test who received further assessment due to clinical recommendation


[^] target population is not the total of age eligible individuals for screening

Breast cancer accounts for **11.7% (2.261 million new cases)** of the global cancer incidence and **6.9% (684 996 deaths)** of the global cancer mortality (Source: GLOBOCAN 2020).

This fact sheet presents the screening protocol, number of women screened and performance indicators according to the most up-to-date information received from **75 countries**.

The year of data collection may differ across the countries.

Reporting year	Screening test	Screening interval (years)	Age group	Number screened	Examination coverage (%)	Proportion advised further assessment (%)	Further assessment participation rate (%)	Detection rate of CIS (/1,000)	Detection rate of invasive cancer (/1,000)	PPV to detect CIS invasive cancer (%)	
EUROPE											
Austria	2014	Mx	2	50-69	196,049	36.9	2.4	—	—	—	
Belgium, Brussels	2013	Mx	2	50-69	6,040	10.4	11.8	—	1.0	5.5	
Belgium, Flanders	2014	Mx	2	50-69	204,101	50.2	2.6	91.7	1.0	4.3	
Belgium, Wallonia	2013	Mx	2	50-69	18,063	8.0	8.5	88.6	1.2	5.2	
Bulgaria	2016	No programme									
Croatia	2016	No programme									
Cyprus, Nicosia	2013	Mx	2	50-69	8,091	42.2	10.1	79.0	1.0	2.5	
Czechia	2013	Mx	2	50-69	418,475	59.1	7.7	100.0	0.6	4.7	
Denmark	2013	Mx	2	50-69	257,224	72.0	2.6	100.0	0.6	6.2	
Estonia	2014	Mx	2	50-64	33,106	45.9	2.6	—	0.1	4.3	
Finland	2012	Mx	2	50-69	284,433	76.1	2.6	99.9	0.7	5.0	
France	2012	Mx	2	50-69	2,146,905	52.3	9.4	96.0	1.0	5.7	
Germany	2012	Mx	2	50-69	2,823,631	52.7	4.6	97.8	1.2	4.9	
Hungary	2013	Mx	2	50-64	210,887	38.4	6.1	91.9	0.4	3.2	
Ireland	2013	Mx	2	50-64	144,508	76.2	3.8	99.4	1.3	5.0	
Italy	2013	Mx	½	50-69	1,515,395	39.1	5.8	98.0	0.7	3.6	
Latvia	2016	No programme									
Lithuania	2014	Mx	2	50-69	93,113	44.9	7.3	—	—	—	
Luxembourg	2013	Mx	2	50-69	17,893	60.4	6.0	97.9	1.0	5.4	
Malta	2013	Mx	3	50-69	7,169	36.4	10.3	99.2	1.3	4.9	
Netherlands	2013	Mx	2	50-69	841,444	77.5	2.3	98.6	1.4	4.6	
Norway	2020	Mx	2	50-69	—	—	—	—	—	—	
Poland	2013	Mx	2	50-69	1,141,351	44.0	4.0	96.0	0.1	5.9	
Portugal, Alentejo	2013	Mx	2	50-69	20,589	41.9	1.6	94.3	0.4	1.9	
Portugal, Azores	2013	Mx	2	50-69	7,808	50.1	3.2	100.0	0.3	3.6	
Portugal, Centre	2013	Mx	2	50-69	82,561	53.2	2.5	97.8	0.0	2.6	
Portugal, Lisboa	2013	Mx	2	50-69	25,960	13.6	1.9	93.7	0.4	4.4	
Portugal, Norte	2013	Mx	2	50-69	82,740	34.0	5.8	98.2	0.7	3.5	
Romania	2016	No programme									
Slovakia	2016	No programme									
Slovenia	2013	Mx	2	50-69	25,695	19.1	3.4	99.7	2.0	4.1	
Spain	2013	Mx	2	50-69	1,654,865	59.7	4.5	99.3	0.6	3.9	
Spain, Basque Country	2018	Mx	2	50-69	115,420	74.5	0.8	99.6	0.8	4.3	
Sweden, Stockholm Gotland	2013	Mx	2	50-69	83,451	70.0	2.4	98.9	0.9	5.2	
United Kingdom, England	2013	Mx	3	50-70	1,874,528	85.5	3.9	99.2	1.7	6.7	
United Kingdom, Northern Ireland	2013	Mx	3	50-70	57,110	80.0	3.4	99.6	1.0	5.4	
United Kingdom, Scotland	2013	Mx	3	50-70	172,427	72.5	5.0	99.4	1.2	6.5	
United Kingdom, Wales	2013	Mx	3	50-70	101,897	74.4	4.8	99.3	2.1	8.1	
OCEANIA											
Australia	2018	Mx	2	50-74	2,071,814	41.4	2.4	—	0.7	2.9	



Data from **75 countries**

- Breast programme
- No programme
- No data available
- No data

All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization / International Agency for Research on Cancer concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate borderlines for which there may not yet be full agreement.

Data source: **CanScreen5**
Map production: **IARC**
World Health Organization